SIMILAR PATTERN OF AMINO ACIDS MAPPED TO 'M77'

List of Similar Pattern of Amino Acids

Hit pattern: 3D amino acid arrangements similar to known drug binding site
Query pattern: Residues from known binding site for annotated drug that match the hit pattern

(Click on the DrReposER ID to view details on interfaces and similar patterns of amino acids)
(Click on the view link on the last column to view superposed patterns of amino acids)

Filter list by:

	DrReposER ID / Desc.	Hit PDBID	Hit Macromolecule	Res. Matches	Interface	HETATM	RMSD	Dali Z-score	Seq. Identity (%)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1OPJ_B_STIB4_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1)	5vef	SERINE/THREONINE-PRO TEIN KINASE PAK 4 (Homo sapiens)	6 / 12	VAL A 335 ALA A 348 GLU A 366 VAL A 379 PHE A 397 GLY A 401	M77 A 601 (-4.5A) M77 A 601 ( 3.5A) None None M77 A 601 (-4.1A) M77 A 601 ( 4.8A)	0.89A	1opjB-5vefA: 21.9	1opjB-5vefA: 22.92
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2EVA_A_ADNA498_1 (TAK1 KINASE - TAB1 CHIMERA FUSION PROTEIN)	5vef	SERINE/THREONINE-PRO TEIN KINASE PAK 4 (Homo sapiens)	7 / 11	GLY A 328 GLY A 330 VAL A 335 ALA A 348 MET A 395 LEU A 447 ASP A 458	M77 A 601 (-3.4A) M77 A 601 (-2.6A) M77 A 601 (-4.5A) M77 A 601 ( 3.5A) M77 A 601 ( 2.9A) M77 A 601 (-4.6A) M77 A 601 ( 3.5A)	0.64A	2evaA-5vefA: 25.7	2evaA-5vefA: 26.10
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2FUM_D_MIXD3539_1 (PROBABLE SERINE/THREONINE-PRO TEIN KINASE PKNB)	5vef	SERINE/THREONINE-PRO TEIN KINASE PAK 4 (Homo sapiens)	7 / 12	GLY A 328 GLY A 330 VAL A 335 ALA A 348 MET A 395 LYS A 442 ASP A 458	M77 A 601 (-3.4A) M77 A 601 (-2.6A) M77 A 601 (-4.5A) M77 A 601 ( 3.5A) M77 A 601 ( 2.9A) None M77 A 601 ( 3.5A)	0.91A	2fumD-5vefA: 25.4	2fumD-5vefA: 27.43
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2HYY_C_STIC600_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1)	5vef	SERINE/THREONINE-PRO TEIN KINASE PAK 4 (Homo sapiens)	7 / 12	VAL A 335 ALA A 348 GLU A 366 VAL A 379 PHE A 397 GLY A 401 LEU A 447	M77 A 601 (-4.5A) M77 A 601 ( 3.5A) None None M77 A 601 (-4.1A) M77 A 601 ( 4.8A) M77 A 601 (-4.6A)	0.77A	2hyyC-5vefA: 22.8	2hyyC-5vefA: 21.75
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2Y7J_A_B49A1294_1 (PHOSPHORYLASE B KINASE GAMMA CATALYTIC CHAIN, TESTIS/LIVER ISOFORM)	5vef	SERINE/THREONINE-PRO TEIN KINASE PAK 4 (Homo sapiens)	6 / 12	ILE A 327 VAL A 335 ALA A 348 GLY A 401 LEU A 447 ASP A 458	M77 A 601 ( 4.8A) M77 A 601 (-4.5A) M77 A 601 ( 3.5A) M77 A 601 ( 4.8A) M77 A 601 (-4.6A) M77 A 601 ( 3.5A)	0.57A	2y7jA-5vefA: 30.2	2y7jA-5vefA: 26.30
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2Y7J_B_B49B1294_1 (PHOSPHORYLASE B KINASE GAMMA CATALYTIC CHAIN, TESTIS/LIVER ISOFORM)	5vef	SERINE/THREONINE-PRO TEIN KINASE PAK 4 (Homo sapiens)	6 / 10	ILE A 327 VAL A 335 ALA A 348 GLY A 401 LEU A 447 ASP A 458	M77 A 601 ( 4.8A) M77 A 601 (-4.5A) M77 A 601 ( 3.5A) M77 A 601 ( 4.8A) M77 A 601 (-4.6A) M77 A 601 ( 3.5A)	0.64A	2y7jB-5vefA: 30.4	2y7jB-5vefA: 26.30
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3MIY_A_B49A1_1 (TYROSINE-PROTEIN KINASE ITK/TSK)	5vef	SERINE/THREONINE-PRO TEIN KINASE PAK 4 (Homo sapiens)	9 / 11	ILE A 327 ALA A 348 LYS A 350 VAL A 379 PHE A 397 GLY A 401 LEU A 447 SER A 457 ASP A 458	M77 A 601 ( 4.8A) M77 A 601 ( 3.5A) M77 A 601 ( 4.7A) None M77 A 601 (-4.1A) M77 A 601 ( 4.8A) M77 A 601 (-4.6A) M77 A 601 (-3.2A) M77 A 601 ( 3.5A)	0.87A	3miyA-5vefA: 24.1	3miyA-5vefA: 27.07
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3MIY_B_B49B2_1 (TYROSINE-PROTEIN KINASE ITK/TSK)	5vef	SERINE/THREONINE-PRO TEIN KINASE PAK 4 (Homo sapiens)	7 / 9	ILE A 327 ALA A 348 LYS A 350 PHE A 397 GLY A 401 LEU A 447 SER A 457	M77 A 601 ( 4.8A) M77 A 601 ( 3.5A) M77 A 601 ( 4.7A) M77 A 601 (-4.1A) M77 A 601 ( 4.8A) M77 A 601 (-4.6A) M77 A 601 (-3.2A)	0.69A	3miyB-5vefA: 23.8	3miyB-5vefA: 27.07
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3TI1_A_B49A299_1 (CYCLIN-DEPENDENT KINASE 2)	5vef	SERINE/THREONINE-PRO TEIN KINASE PAK 4 (Homo sapiens)	5 / 9	ILE A 327 ALA A 348 VAL A 379 PHE A 397 LEU A 447	M77 A 601 ( 4.8A) M77 A 601 ( 3.5A) None M77 A 601 (-4.1A) M77 A 601 (-4.6A)	0.56A	3ti1A-5vefA: 25.6	3ti1A-5vefA: 27.78
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3UE4_B_DB8B601_1 (TYROSINE-PROTEIN KINASE ABL1)	5vef	SERINE/THREONINE-PRO TEIN KINASE PAK 4 (Homo sapiens)	7 / 12	VAL A 335 ALA A 348 GLU A 366 VAL A 379 PHE A 397 GLY A 401 LEU A 447	M77 A 601 (-4.5A) M77 A 601 ( 3.5A) None None M77 A 601 (-4.1A) M77 A 601 ( 4.8A) M77 A 601 (-4.6A)	0.80A	3ue4B-5vefA: 25.2	3ue4B-5vefA: 21.92
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3WZD_A_LEVA1201_2 (VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2)	5vef	SERINE/THREONINE-PRO TEIN KINASE PAK 4 (Homo sapiens)	4 / 5	ILE A 369 VAL A 379 LEU A 447 ASP A 458	None None M77 A 601 (-4.6A) M77 A 601 ( 3.5A)	1.17A	3wzdA-5vefA: 22.3	3wzdA-5vefA: 26.72
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4AG8_A_AXIA2000_1 (VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2)	5vef	SERINE/THREONINE-PRO TEIN KINASE PAK 4 (Homo sapiens)	8 / 12	VAL A 335 ALA A 348 LYS A 350 GLU A 366 VAL A 379 PHE A 397 GLY A 401 LEU A 447	M77 A 601 (-4.5A) M77 A 601 ( 3.5A) M77 A 601 ( 4.7A) None None M77 A 601 (-4.1A) M77 A 601 ( 4.8A) M77 A 601 (-4.6A)	0.70A	4ag8A-5vefA: 22.0	4ag8A-5vefA: 26.57
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4AGD_A_B49A2000_1 (VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2)	5vef	SERINE/THREONINE-PRO TEIN KINASE PAK 4 (Homo sapiens)	5 / 11	ALA A 348 VAL A 379 PHE A 397 GLY A 401 LEU A 447	M77 A 601 ( 3.5A) None M77 A 601 (-4.1A) M77 A 601 ( 4.8A) M77 A 601 (-4.6A)	0.49A	4agdA-5vefA: 21.3	4agdA-5vefA: 26.01
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4ASD_A_BAXA1500_1 (VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2)	5vef	SERINE/THREONINE-PRO TEIN KINASE PAK 4 (Homo sapiens)	7 / 12	VAL A 335 ALA A 348 LYS A 350 GLU A 366 PHE A 397 GLY A 401 HIS A 438	M77 A 601 (-4.5A) M77 A 601 ( 3.5A) M77 A 601 ( 4.7A) None M77 A 601 (-4.1A) M77 A 601 ( 4.8A) None	0.58A	4asdA-5vefA: 21.8	4asdA-5vefA: 26.01
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4KS8_A_B49A701_1 (SERINE/THREONINE-PRO TEIN KINASE PAK 6)	5vef	SERINE/THREONINE-PRO TEIN KINASE PAK 4 (Homo sapiens)	6 / 10	ALA A 348 VAL A 379 MET A 395 PHE A 397 LEU A 398 GLY A 400	M77 A 601 ( 3.5A) None M77 A 601 ( 2.9A) M77 A 601 (-4.1A) M77 A 601 (-4.4A) None	1.21A	4ks8A-5vefA: 44.6	4ks8A-5vefA: 70.03
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4KS8_A_B49A701_1 (SERINE/THREONINE-PRO TEIN KINASE PAK 6)	5vef	SERINE/THREONINE-PRO TEIN KINASE PAK 4 (Homo sapiens)	10 / 10	ILE A 327 ALA A 348 VAL A 379 MET A 395 PHE A 397 LEU A 398 GLY A 401 LEU A 447 SER A 457 ASP A 458	M77 A 601 ( 4.8A) M77 A 601 ( 3.5A) None M77 A 601 ( 2.9A) M77 A 601 (-4.1A) M77 A 601 (-4.4A) M77 A 601 ( 4.8A) M77 A 601 (-4.6A) M77 A 601 (-3.2A) M77 A 601 ( 3.5A)	0.53A	4ks8A-5vefA: 44.6	4ks8A-5vefA: 70.03
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4QMZ_A_B49A401_1 (SERINE/THREONINE-PRO TEIN KINASE 24)	5vef	SERINE/THREONINE-PRO TEIN KINASE PAK 4 (Homo sapiens)	7 / 12	ILE A 327 GLY A 328 VAL A 335 ALA A 348 MET A 395 LEU A 398 LEU A 447	M77 A 601 ( 4.8A) M77 A 601 (-3.4A) M77 A 601 (-4.5A) M77 A 601 ( 3.5A) M77 A 601 ( 2.9A) M77 A 601 (-4.4A) M77 A 601 (-4.6A)	0.62A	4qmzA-5vefA: 37.4	4qmzA-5vefA: 35.80
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4QMZ_A_B49A401_1 (SERINE/THREONINE-PRO TEIN KINASE 24)	5vef	SERINE/THREONINE-PRO TEIN KINASE PAK 4 (Homo sapiens)	6 / 12	ILE A 327 GLY A 328 VAL A 335 LEU A 398 GLY A 400 LEU A 447	M77 A 601 ( 4.8A) M77 A 601 (-3.4A) M77 A 601 (-4.5A) M77 A 601 (-4.4A) None M77 A 601 (-4.6A)	0.85A	4qmzA-5vefA: 37.4	4qmzA-5vefA: 35.80
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5I9Y_A_1N1A1001_1 (EPHRIN TYPE-A RECEPTOR 2)	5vef	SERINE/THREONINE-PRO TEIN KINASE PAK 4 (Homo sapiens)	6 / 12	ILE A 327 ALA A 348 LYS A 350 GLY A 401 LEU A 447 SER A 457	M77 A 601 ( 4.8A) M77 A 601 ( 3.5A) M77 A 601 ( 4.7A) M77 A 601 ( 4.8A) M77 A 601 (-4.6A) M77 A 601 (-3.2A)	0.73A	5i9yA-5vefA: 22.6	5i9yA-5vefA: 26.76
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5LW1_B_ADNB401_1 (MITOGEN-ACTIVATED PROTEIN KINASE 8)	5vef	SERINE/THREONINE-PRO TEIN KINASE PAK 4 (Homo sapiens)	5 / 9	ILE A 327 GLY A 328 VAL A 335 ALA A 348 MET A 395	M77 A 601 ( 4.8A) M77 A 601 (-3.4A) M77 A 601 (-4.5A) M77 A 601 ( 3.5A) M77 A 601 ( 2.9A)	0.55A	5lw1B-5vefA: 23.9	5lw1B-5vefA: 15.10
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5P9I_A_1E8A701_1 (TYROSINE-PROTEIN KINASE BTK)	5vef	SERINE/THREONINE-PRO TEIN KINASE PAK 4 (Homo sapiens)	6 / 12	GLY A 330 VAL A 335 ALA A 348 LYS A 350 LEU A 447 SER A 457	M77 A 601 (-2.6A) M77 A 601 (-4.5A) M77 A 601 ( 3.5A) M77 A 601 ( 4.7A) M77 A 601 (-4.6A) M77 A 601 (-3.2A)	0.93A	5p9iA-5vefA: 24.7	5p9iA-5vefA: 23.01
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5TE0_A_XINA401_1 (AP2-ASSOCIATED PROTEIN KINASE 1)	5vef	SERINE/THREONINE-PRO TEIN KINASE PAK 4 (Homo sapiens)	6 / 12	ALA A 348 GLU A 366 VAL A 379 PHE A 397 GLY A 401 LEU A 447	M77 A 601 ( 3.5A) None None M77 A 601 (-4.1A) M77 A 601 ( 4.8A) M77 A 601 (-4.6A)	0.60A	5te0A-5vefA: 25.4	5te0A-5vefA: 28.38
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5YU9_B_1E8B1101_1 (EPIDERMAL GROWTH FACTOR RECEPTOR)	5vef	SERINE/THREONINE-PRO TEIN KINASE PAK 4 (Homo sapiens)	7 / 12	GLY A 328 VAL A 335 ALA A 348 LYS A 350 MET A 395 LEU A 447 ASP A 458	M77 A 601 (-3.4A) M77 A 601 (-4.5A) M77 A 601 ( 3.5A) M77 A 601 ( 4.7A) M77 A 601 ( 2.9A) M77 A 601 (-4.6A) M77 A 601 ( 3.5A)	1.20A	5yu9B-5vefA: 22.7	5yu9B-5vefA: 13.29
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6BRD_B_RFPB502_2 (RIFAMPIN MONOOXYGENASE)	5vef	SERINE/THREONINE-PRO TEIN KINASE PAK 4 (Homo sapiens)	4 / 6	VAL A 476 LEU A 308 MET A 395 ARG A 371	SEP A 474 ( 4.4A) None M77 A 601 ( 2.9A) None	0.99A	6brdB-5vefA: 1.2	6brdB-5vefA: 13.59

[["DrReposER ID","Desc.","Hit PDB","Hit molecule","Hit organism","Res. no.","Interface","HETATM","RMSD","Z-score","Seq ID"],["1OPJ_B_STIB4_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","5vef","SERINE\/THREONINE-PROTEIN KINASE PAK 4","Homo sapiens",6,"VAL A 335;ALA A 348;GLU A 366;VAL A 379;PHE A 397;GLY A 401","M77 A 601 (-4.5A);M77 A 601 ( 3.5A);None;None;M77 A 601 (-4.1A);M77 A 601 ( 4.8A)","0.89A","1opjB-5vefA:21.9",null],["2EVA_A_ADNA498_1","TAK1 KINASE - TAB1 CHIMERA FUSION PROTEIN","5vef","SERINE\/THREONINE-PROTEIN KINASE PAK 4","Homo sapiens",7,"GLY A 328;GLY A 330;VAL A 335;ALA A 348;MET A 395;LEU A 447;ASP A 458","M77 A 601 (-3.4A);M77 A 601 (-2.6A);M77 A 601 (-4.5A);M77 A 601 ( 3.5A);M77 A 601 ( 2.9A);M77 A 601 (-4.6A);M77 A 601 ( 3.5A)","0.64A","2evaA-5vefA:25.7","1opjB-5vefA:22.92"],["2FUM_D_MIXD3539_1","PROBABLE SERINE\/THREONINE-PROTEIN KINASE PKNB","5vef","SERINE\/THREONINE-PROTEIN KINASE PAK 4","Homo sapiens",7,"GLY A 328;GLY A 330;VAL A 335;ALA A 348;MET A 395;LYS A 442;ASP A 458","M77 A 601 (-3.4A);M77 A 601 (-2.6A);M77 A 601 (-4.5A);M77 A 601 ( 3.5A);M77 A 601 ( 2.9A);None;M77 A 601 ( 3.5A)","0.91A","2fumD-5vefA:25.4","2evaA-5vefA:26.10"],["2HYY_C_STIC600_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","5vef","SERINE\/THREONINE-PROTEIN KINASE PAK 4","Homo sapiens",7,"VAL A 335;ALA A 348;GLU A 366;VAL A 379;PHE A 397;GLY A 401;LEU A 447","M77 A 601 (-4.5A);M77 A 601 ( 3.5A);None;None;M77 A 601 (-4.1A);M77 A 601 ( 4.8A);M77 A 601 (-4.6A)","0.77A","2hyyC-5vefA:22.8","2fumD-5vefA:27.43"],["2Y7J_A_B49A1294_1","PHOSPHORYLASE B KINASE GAMMA CATALYTIC CHAIN, TESTIS\/LIVER ISOFORM","5vef","SERINE\/THREONINE-PROTEIN KINASE PAK 4","Homo sapiens",6,"ILE A 327;VAL A 335;ALA A 348;GLY A 401;LEU A 447;ASP A 458","M77 A 601 ( 4.8A);M77 A 601 (-4.5A);M77 A 601 ( 3.5A);M77 A 601 ( 4.8A);M77 A 601 (-4.6A);M77 A 601 ( 3.5A)","0.57A","2y7jA-5vefA:30.2","2hyyC-5vefA:21.75"],["2Y7J_B_B49B1294_1","PHOSPHORYLASE B KINASE GAMMA CATALYTIC CHAIN, TESTIS\/LIVER ISOFORM","5vef","SERINE\/THREONINE-PROTEIN KINASE PAK 4","Homo sapiens",6,"ILE A 327;VAL A 335;ALA A 348;GLY A 401;LEU A 447;ASP A 458","M77 A 601 ( 4.8A);M77 A 601 (-4.5A);M77 A 601 ( 3.5A);M77 A 601 ( 4.8A);M77 A 601 (-4.6A);M77 A 601 ( 3.5A)","0.64A","2y7jB-5vefA:30.4","2y7jA-5vefA:26.30"],["3MIY_A_B49A1_1","TYROSINE-PROTEIN KINASE ITK\/TSK","5vef","SERINE\/THREONINE-PROTEIN KINASE PAK 4","Homo sapiens",9,"ILE A 327;ALA A 348;LYS A 350;VAL A 379;PHE A 397;GLY A 401;LEU A 447;SER A 457;ASP A 458","M77 A 601 ( 4.8A);M77 A 601 ( 3.5A);M77 A 601 ( 4.7A);None;M77 A 601 (-4.1A);M77 A 601 ( 4.8A);M77 A 601 (-4.6A);M77 A 601 (-3.2A);M77 A 601 ( 3.5A)","0.87A","3miyA-5vefA:24.1","2y7jB-5vefA:26.30"],["3MIY_B_B49B2_1","TYROSINE-PROTEIN KINASE ITK\/TSK","5vef","SERINE\/THREONINE-PROTEIN KINASE PAK 4","Homo sapiens",7,"ILE A 327;ALA A 348;LYS A 350;PHE A 397;GLY A 401;LEU A 447;SER A 457","M77 A 601 ( 4.8A);M77 A 601 ( 3.5A);M77 A 601 ( 4.7A);M77 A 601 (-4.1A);M77 A 601 ( 4.8A);M77 A 601 (-4.6A);M77 A 601 (-3.2A)","0.69A","3miyB-5vefA:23.8","3miyA-5vefA:27.07"],["3TI1_A_B49A299_1","CYCLIN-DEPENDENT KINASE 2","5vef","SERINE\/THREONINE-PROTEIN KINASE PAK 4","Homo sapiens",5,"ILE A 327;ALA A 348;VAL A 379;PHE A 397;LEU A 447","M77 A 601 ( 4.8A);M77 A 601 ( 3.5A);None;M77 A 601 (-4.1A);M77 A 601 (-4.6A)","0.56A","3ti1A-5vefA:25.6","3miyB-5vefA:27.07"],["3UE4_B_DB8B601_1","TYROSINE-PROTEIN KINASE ABL1","5vef","SERINE\/THREONINE-PROTEIN KINASE PAK 4","Homo sapiens",7,"VAL A 335;ALA A 348;GLU A 366;VAL A 379;PHE A 397;GLY A 401;LEU A 447","M77 A 601 (-4.5A);M77 A 601 ( 3.5A);None;None;M77 A 601 (-4.1A);M77 A 601 ( 4.8A);M77 A 601 (-4.6A)","0.80A","3ue4B-5vefA:25.2","3ti1A-5vefA:27.78"],["3WZD_A_LEVA1201_2","VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2","5vef","SERINE\/THREONINE-PROTEIN KINASE PAK 4","Homo sapiens",4,"ILE A 369;VAL A 379;LEU A 447;ASP A 458","None;None;M77 A 601 (-4.6A);M77 A 601 ( 3.5A)","1.17A","3wzdA-5vefA:22.3","3ue4B-5vefA:21.92"],["4AG8_A_AXIA2000_1","VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2","5vef","SERINE\/THREONINE-PROTEIN KINASE PAK 4","Homo sapiens",8,"VAL A 335;ALA A 348;LYS A 350;GLU A 366;VAL A 379;PHE A 397;GLY A 401;LEU A 447","M77 A 601 (-4.5A);M77 A 601 ( 3.5A);M77 A 601 ( 4.7A);None;None;M77 A 601 (-4.1A);M77 A 601 ( 4.8A);M77 A 601 (-4.6A)","0.70A","4ag8A-5vefA:22.0","3wzdA-5vefA:26.72"],["4AGD_A_B49A2000_1","VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2","5vef","SERINE\/THREONINE-PROTEIN KINASE PAK 4","Homo sapiens",5,"ALA A 348;VAL A 379;PHE A 397;GLY A 401;LEU A 447","M77 A 601 ( 3.5A);None;M77 A 601 (-4.1A);M77 A 601 ( 4.8A);M77 A 601 (-4.6A)","0.49A","4agdA-5vefA:21.3","4ag8A-5vefA:26.57"],["4ASD_A_BAXA1500_1","VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2","5vef","SERINE\/THREONINE-PROTEIN KINASE PAK 4","Homo sapiens",7,"VAL A 335;ALA A 348;LYS A 350;GLU A 366;PHE A 397;GLY A 401;HIS A 438","M77 A 601 (-4.5A);M77 A 601 ( 3.5A);M77 A 601 ( 4.7A);None;M77 A 601 (-4.1A);M77 A 601 ( 4.8A);None","0.58A","4asdA-5vefA:21.8","4agdA-5vefA:26.01"],["4KS8_A_B49A701_1","SERINE\/THREONINE-PROTEIN KINASE PAK 6","5vef","SERINE\/THREONINE-PROTEIN KINASE PAK 4","Homo sapiens",6,"ALA A 348;VAL A 379;MET A 395;PHE A 397;LEU A 398;GLY A 400","M77 A 601 ( 3.5A);None;M77 A 601 ( 2.9A);M77 A 601 (-4.1A);M77 A 601 (-4.4A);None","1.21A","4ks8A-5vefA:44.6","4asdA-5vefA:26.01"],["4KS8_A_B49A701_1","SERINE\/THREONINE-PROTEIN KINASE PAK 6","5vef","SERINE\/THREONINE-PROTEIN KINASE PAK 4","Homo sapiens",10,"ILE A 327;ALA A 348;VAL A 379;MET A 395;PHE A 397;LEU A 398;GLY A 401;LEU A 447;SER A 457;ASP A 458","M77 A 601 ( 4.8A);M77 A 601 ( 3.5A);None;M77 A 601 ( 2.9A);M77 A 601 (-4.1A);M77 A 601 (-4.4A);M77 A 601 ( 4.8A);M77 A 601 (-4.6A);M77 A 601 (-3.2A);M77 A 601 ( 3.5A)","0.53A","4ks8A-5vefA:44.6","4ks8A-5vefA:70.03"],["4QMZ_A_B49A401_1","SERINE\/THREONINE-PROTEIN KINASE 24","5vef","SERINE\/THREONINE-PROTEIN KINASE PAK 4","Homo sapiens",7,"ILE A 327;GLY A 328;VAL A 335;ALA A 348;MET A 395;LEU A 398;LEU A 447","M77 A 601 ( 4.8A);M77 A 601 (-3.4A);M77 A 601 (-4.5A);M77 A 601 ( 3.5A);M77 A 601 ( 2.9A);M77 A 601 (-4.4A);M77 A 601 (-4.6A)","0.62A","4qmzA-5vefA:37.4","4ks8A-5vefA:70.03"],["4QMZ_A_B49A401_1","SERINE\/THREONINE-PROTEIN KINASE 24","5vef","SERINE\/THREONINE-PROTEIN KINASE PAK 4","Homo sapiens",6,"ILE A 327;GLY A 328;VAL A 335;LEU A 398;GLY A 400;LEU A 447","M77 A 601 ( 4.8A);M77 A 601 (-3.4A);M77 A 601 (-4.5A);M77 A 601 (-4.4A);None;M77 A 601 (-4.6A)","0.85A","4qmzA-5vefA:37.4","4qmzA-5vefA:35.80"],["5I9Y_A_1N1A1001_1","EPHRIN TYPE-A RECEPTOR 2","5vef","SERINE\/THREONINE-PROTEIN KINASE PAK 4","Homo sapiens",6,"ILE A 327;ALA A 348;LYS A 350;GLY A 401;LEU A 447;SER A 457","M77 A 601 ( 4.8A);M77 A 601 ( 3.5A);M77 A 601 ( 4.7A);M77 A 601 ( 4.8A);M77 A 601 (-4.6A);M77 A 601 (-3.2A)","0.73A","5i9yA-5vefA:22.6","4qmzA-5vefA:35.80"],["5LW1_B_ADNB401_1","MITOGEN-ACTIVATED PROTEIN KINASE 8","5vef","SERINE\/THREONINE-PROTEIN KINASE PAK 4","Homo sapiens",5,"ILE A 327;GLY A 328;VAL A 335;ALA A 348;MET A 395","M77 A 601 ( 4.8A);M77 A 601 (-3.4A);M77 A 601 (-4.5A);M77 A 601 ( 3.5A);M77 A 601 ( 2.9A)","0.55A","5lw1B-5vefA:23.9","5i9yA-5vefA:26.76"],["5P9I_A_1E8A701_1","TYROSINE-PROTEIN KINASE BTK","5vef","SERINE\/THREONINE-PROTEIN KINASE PAK 4","Homo sapiens",6,"GLY A 330;VAL A 335;ALA A 348;LYS A 350;LEU A 447;SER A 457","M77 A 601 (-2.6A);M77 A 601 (-4.5A);M77 A 601 ( 3.5A);M77 A 601 ( 4.7A);M77 A 601 (-4.6A);M77 A 601 (-3.2A)","0.93A","5p9iA-5vefA:24.7","5lw1B-5vefA:15.10"],["5TE0_A_XINA401_1","AP2-ASSOCIATED PROTEIN KINASE 1","5vef","SERINE\/THREONINE-PROTEIN KINASE PAK 4","Homo sapiens",6,"ALA A 348;GLU A 366;VAL A 379;PHE A 397;GLY A 401;LEU A 447","M77 A 601 ( 3.5A);None;None;M77 A 601 (-4.1A);M77 A 601 ( 4.8A);M77 A 601 (-4.6A)","0.60A","5te0A-5vefA:25.4","5p9iA-5vefA:23.01"],["5YU9_B_1E8B1101_1","EPIDERMAL GROWTH FACTOR RECEPTOR","5vef","SERINE\/THREONINE-PROTEIN KINASE PAK 4","Homo sapiens",7,"GLY A 328;VAL A 335;ALA A 348;LYS A 350;MET A 395;LEU A 447;ASP A 458","M77 A 601 (-3.4A);M77 A 601 (-4.5A);M77 A 601 ( 3.5A);M77 A 601 ( 4.7A);M77 A 601 ( 2.9A);M77 A 601 (-4.6A);M77 A 601 ( 3.5A)","1.20A","5yu9B-5vefA:22.7","5te0A-5vefA:28.38"],["6BRD_B_RFPB502_2","RIFAMPIN MONOOXYGENASE","5vef","SERINE\/THREONINE-PROTEIN KINASE PAK 4","Homo sapiens",4,"VAL A 476;LEU A 308;MET A 395;ARG A 371","SEP A 474 ( 4.4A);None;M77 A 601 ( 2.9A);None","0.99A","6brdB-5vefA:1.2","5yu9B-5vefA:13.29"]]